
    intolerable high amount of adverse events
  
['neuropathic pain']
['loxapine']

        Inclusion Criteria:

          -  Primarily chemotherapy-induced neuropathic pain (including mixed pain) for at least 3
             months refractory to at least one analgesic compound

          -  Neuropathic pain >= 4 (11-point numeric pain scale) at screening visit (including
             mixed pain)

          -  Age >= 18 years

          -  Body weight between 50 and 150 kg

          -  Given written informed consent

        Exclusion Criteria:

          -  Participation in other interventional clinical studies (currently or within the last 3
             months)

          -  Parkinson's disease, movement disorders (extrapyramidal signs and symptoms) associated
             with antipsychotics, neuroleptic malignant syndrome, other syndromes associated with
             antipsychotics

          -  Severe hypotension with a syncope in history, glaucoma, urinary retention, epilepsy or
             other seizure disorders in history, severe dementia, dementia-related psychosis in
             history, malignancies with a life expectancy of less than 6 months, breast cancer in
             history, other life-threatening conditions

          -  Corrected QT interval (QTc) > 460 ms (females) or > 450 ms (males)

          -  Known alcohol and/or drug abuse

          -  Concomitant intake of antipsychotics, dopamine agonists (Levodopa, bromocriptine,
             lisuride, pergolide, ropinirole, cabergoline, pramipexole, apomorphine),
             alpha-receptor blocking compounds

          -  Compounds with a strong evidence for a clinically relevant QT interval prolongation or
             torsade de pointes risk increase

          -  Strong inhibitors of CYP1A2, CYP2D6, or CYP3A4

          -  Known CYP2D6 Poor metabolizer status

          -  Pregnancy or lactation period

          -  Missing or insufficient contraception in pre- or perimenopausal women

          -  Close Affiliation with the investigational site
      